

# Clinical trials of eprosartan+ACE inhibitor

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 heart failure

| Trial   | Treatments   | Patients  | Trials design and methods       |
|---|--|---|---------------------------------|
| <b>eprosartan+ACE inhibitor vs ACE inhibitor only</b>     |  |   |                                 |
| <a href="#">ADEPT, 2001</a><br>n=18/18<br>follow-up: 8 wk | Eprosartan, 400 to 800 mg twice daily<br>versus<br>Placebo | patients with stable New York Heart<br>Association class II-IV CHF receiving<br>ACE inhibitor therapy | Parallel groups<br>double blind |

More details and results :

- angiotensin-receptor blockers for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q65>
- angiotensin-receptor blockers for heart failure in patients already receiving ACE inhibitor at <http://www.trialresultscenter.org/go-Q68>

## References

### ADEPT, 2001:

Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 2001 May;141:800-7 [[11320369](#)]